Introduction
PD, death, hyperphosphatemia, Hyperphosphatemia
ADVERSE EVENTS, HYPERPHOSPHATEMIA, END-STAGE KIDNEY DISEASE, CHRONIC KIDNEY DISEASE (CKD), HYPERPHOSPHATEMIA
Chronic kidney disease (CKD) is a serious health burden in the general population, leading to a high rate of death and the development of end-stage kidney disease [Hyperphosphatemia can directly lead to calcification of the myocardium, heart valves, blood vessels, and other tissues [As to poor phosphorus control in PD, patient variability for factors other than phosphate load from food, namely dialytic and kidney function removal of phosphate and phosphate binder efficacy, needs to be considered. Regarding phosphate removal, weekly phosphorus removal through the peritoneum in PD is lower than with HD; residual kidney function substantially contributes to phosphorus removal in PD patients. Thus, as residual kidney function declines, the risk of hyperphosphatemia increases.Phosphate binders have proven effective in reducing serum phosphorus levels, but their use is often limited by adverse events (AEs) and/or heavy pill burden [Tenapanor is a non-polymeric drug that acts via selective inhibition of intestinal sodium/hydrogen exchanger 3 (NHE3) transporters, resulting in decreased intestinal phosphate absorption [The preclinical and clinical data supporting the use of tenapanor in patients who develop hyperphosphatemia while undergoing dialysis are encouraging, with significant reductions in serum phosphorus to target levels in all tenapanor groups, a small pill burden, and a tolerable safety profile [